Andrew Waight
Overview
Explore the profile of Andrew Waight including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
162
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rollins Z, Widatalla T, Waight A, Cheng A, Metwally E
Bioinformatics
. 2024 Apr;
40(5).
PMID: 38627249
Motivation: Pre-trained protein language and/or structural models are often fine-tuned on drug development properties (i.e. developability properties) to accelerate drug discovery initiatives. However, these models generally rely on a single...
2.
Prihoda D, Maamary J, Waight A, Juan V, Fayadat-Dilman L, Svozil D, et al.
MAbs
. 2022 Feb;
14(1):2020203.
PMID: 35133949
Despite recent advances in transgenic animal models and display technologies, humanization of mouse sequences remains one of the main routes for therapeutic antibody development. Traditionally, humanization is manual, laborious, and...
3.
Kapoor K, Finer-Moore J, Pedersen B, Caboni L, Waight A, Hillig R, et al.
Proc Natl Acad Sci U S A
. 2016 Apr;
113(17):4711-6.
PMID: 27078104
Cancerous cells have an acutely increased demand for energy, leading to increased levels of human glucose transporter 1 (hGLUT1). This up-regulation suggests hGLUT1 as a target for therapeutic inhibitors addressing...
4.
Erlanson D, McDowell R, He M, Randal M, Simmons R, Kung J, et al.
J Am Chem Soc
. 2003 May;
125(19):5602-3.
PMID: 12733877
Protein tyrosine phosphatases play important roles in many signaling cascades involved in human disease. The identification of druglike inhibitors for these targets is a major challenge, and the discovery of...